Toxicity study in naïve mice
Awarded
The competition has ended and a winner has been selected.
- Deadline
- Dec 14, 2025Expired
- Award
- Date of final QA Report (audited), weight 50
Brief
The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to cre-ate new disruptive innovations from Germany. That means products, services and sys-tems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination con-sists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly im-prove the specificity, sus-tainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the IND application at Paul Ehrlich Institute (Germany) we have to show safety of our molecules in animal models. Following extensive discussions and thorough analyses, the PEI has granted approval for a comprehensive toxicological study of our lead candidate in mice. Therefore, we are looking for a service provider to support us regarding pharmaco-toxicological studies
Result
- vivo Science GmbHWinner
- 3Number of tenders received
- -€1Contract value
Previous winners
Who are you up against?
The suppliers who have won similar contracts at BiconY Therapeutics GmbH
Will you bid?
The agent sets up the bid and writes the first draft. Free for 14 days.
Award Criteria
Description
The award criterion price will be evaluated as follows: The lowest bid price according to the Price sheet (Form for offer) will be awarded the highest number of points (5). The number of points for the prices offered will be determined as follows: Points of the bidder = lowest price x 5 / bidder's offered price The score achieved is rounded to two decimal places.
Source
No source found in the documents. Check the weight against the tender documents.
Description
The award criterion Date of final QA Report (audited) will be evaluated as follows: Date Points Till March 27, 2026 5 Till April 3, 2026 4 Till April 11, 2026 3 Till April 18, 2026 2 Till April 25, 2026 1 Till May 29, 2026 0 Please note: 29 May 2026 is the latest possible date A total of up to 10 points can be achieved (5 price points and 5 timeline points for final QA report audited).
Source
No source found in the documents. Check the weight against the tender documents.
From the notice
The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to cre-ate new disruptive innovations from Germany. That means products, services and sys-tems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination con-sists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly im-prove the specificity, sus-tainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the IND application at Paul Ehrlich Institute (Germany) we have to show safety of our molecules in animal models. Following extensive discussions and thorough analyses, the PEI has granted approval for a comprehensive toxicological study of our lead candidate in mice. Therefore, we are looking for a service provider to support us regarding pharmaco-toxicological studies
Contact
bicony.tenderprocedure@fgvw.de- ResultType
- 73000000Main codeResearch and development services and related consultancy services